First Financial Corp Vertex Pharmaceuticals Inc Transaction History

First Financial Corp

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 12, 2024	SELL	$407.69 - $446.08 $35,876 - $39,255	-88 Reduced 75.21%	29 $12,000
Q4 2023 Jan 16, 2024	BUY	$343.0 - $410.68 $20,237 - $24,230	59 Added 101.72%	117 $47,000
Q2 2023 Jul 14, 2023	BUY	$314.42 - $351.91 $2,515 - $2,815	8 Added 16.0%	58 $20,000
Q4 2022 Jan 17, 2023	BUY	$285.76 - $321.48 $6,858 - $7,715	24 Added 92.31%	50 $0
Q3 2019 Oct 15, 2019	BUY	$166.23 - $187.09 $4,321 - $4,864	26 New	26 $4,000

1,716

225M

1.19M

1.56M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $129B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of First Financial Corp , based on Form 13F filings with the SEC.

Stay updated on First Financial Corp with notifications on news.